<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814983</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000993</org_study_id>
    <nct_id>NCT00814983</nct_id>
  </id_info>
  <brief_title>Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft</brief_title>
  <official_title>Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives will be to measure the safety and efficacy of allogeneic stem cell
      transplantation using a peripheral blood stem cell graft that has been depleted of CD45RA+
      Naive T-cells.

      The secondary objectives will be to measure the pace of immune recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cohort of patients (Cohort 1) will be enrolled to receive the currently accepted standard
      approach to myeloablative allogeneic stem cell transplantation. With the exception of volume
      and/or plasma depletion (in cases of donor/recipient ABO incompatibility), the peripheral
      blood stem cell graft will be unmodified. The primary purpose of Cohort 1 is to prospectively
      collect samples for measurement of immune recovery from a relatively homogeneous population
      of patients treated in a uniform manner. Within the limitations of age-matching, patients
      accrued to Cohort 1 will be incorporated into a larger retrospective historical control group
      for purposes of comparison with Cohort 2 of the incidence of grade II-IV acute Graft versus
      Host disease. The experimental aspects of this trial will be the use of a na√Øve T-cell
      depleted peripheral blood stem cell graft (Cohort 2). All other aspects of this stem cell
      transplantation are in line with the standard of care. Recruitment to this trial will be
      stratified by donor type as matched sibling or matched unrelated donor. Patients will be
      conditioned with total body irradiation (1350cGy) and Cyclophosphamide. The donor stem cell
      grafts will come from mobilized peripheral blood of 6/6 HLA-identical family members or 8/8
      (HLA A, B, C, DRB1) allele-level matched unrelated donors.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    IND approval for naive T-cell depletion not obtained
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Incidence of Grade II-IV Acute Graft Versus Host Disease</measure>
    <time_frame>One year from date of transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Immune Recovery</measure>
    <time_frame>3 years</time_frame>
    <description>The time to recovery of T-cell subset, B cell and NK cell recovery will be monitored along with T-Cell proliferative response to mitogens.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>ALL</condition>
  <condition>ANLL</condition>
  <condition>MDS</condition>
  <condition>NHL</condition>
  <arm_group>
    <arm_group_label>Naive T-cell Depleted Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem Cell Transplant No Manipulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Naive T-cell Depleted Stem Cell Transplant</intervention_name>
    <description>The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- &quot;flow-through&quot;fraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant.</description>
    <arm_group_label>Naive T-cell Depleted Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant No Manipulation</intervention_name>
    <description>These patients will be transplanted with unmanipulated peripheral blood stem cells.</description>
    <arm_group_label>Stem Cell Transplant No Manipulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Isolex device from Baxter</intervention_name>
    <arm_group_label>Naive T-cell Depleted Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years.

          -  8/8 or 7/8 HLA-identical matched sibling OR Allele level 8/8 (HLA-A, B, C, DRbeta1)
             matched unrelated donor.

          -  Patients with high risk ALL in first complete remission, with high risk being defined
             by the presence of t(4;11), t(9;22) or t(1;19) or patients presenting with extreme
             hyperleukocytosis (WBC&gt;500,000/ml) or partial remission after initial induction
             therapy.

          -  Adult patients with acute non-lymphocytic Leukemia (ANLL) in first complete remission
             with high-risk cytogenetics (monosomy chromosome 5 or 7, del(5q), abn(3q26), complex
             karyotypic abnormalities) or failure to achieve complete remission after standard
             induction therapy.

          -  All patients with ALL or ANLL in second or subsequent remission or partial remission
             (&lt;5% blasts in bone marrow as measured by flow cytometry).

          -  All patients with CML in chronic (failed interferon and/or Gleevec) or accelerated
             phase.

          -  Patients with myelodysplastic syndrome with International Prognostic Scoring System
             (IPSS) risk category of INT-1 or greater.

          -  Myelofibrosis with myeloid metaplasia

          -  Patients with severe aplastic anemia must have failed immunosuppressive therapy such
             as cyclosporine plus anti-thymocyte globulin.

          -  Patients with a history of CNS disease must have been treated and have no active CNS
             disease at the time of protocol treatment.

          -  ECOG performance status &lt;2

          -  Patients must have adequate function of other organ systems as measured by:

          -  Creatinine clearance (by Cockcroft Gault equation [Appendix IV]) &gt; 30ml/min. Hepatic
             transaminases (ALT/AST) &lt; 4 x normal, bilirubin &lt; 2.0 mg/dl.

          -  Pulmonary function tests demonstrating FVC and FEV1 of &gt;50% of predicted for age and
             DLCO &gt; 50% of predicted.

          -  Ejection fraction of &gt;45% by echocardiogram, radionuclide scan or cardiac MRI.

          -  Patients must be HIV negative.

          -  Patients must not be pregnant.

        Exclusion Criteria:

          -  Patients with &gt; 5% blasts in bone marrow or peripheral circulation.

          -  Patients with rapidly progressive ANLL or ALL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Horwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2008</study_first_submitted>
  <study_first_submitted_qc>December 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2008</study_first_posted>
  <results_first_submitted>September 25, 2013</results_first_submitted>
  <results_first_submitted_qc>September 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2013</results_first_posted>
  <last_update_submitted>September 25, 2013</last_update_submitted>
  <last_update_submitted_qc>September 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myeloablative</keyword>
  <keyword>stem cell</keyword>
  <keyword>naive T-cell depleted</keyword>
  <keyword>allogeneic</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stem Cell Transplant No Manipulation</title>
          <description>Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation</description>
        </group>
        <group group_id="P2">
          <title>Naive T-cell Depleted Stem Cell Transplant</title>
          <description>Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Graft failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stem Cell Transplant No Manipulation</title>
          <description>Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation</description>
        </group>
        <group group_id="B2">
          <title>Naive T-cell Depleted Stem Cell Transplant</title>
          <description>Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Incidence of Grade II-IV Acute Graft Versus Host Disease</title>
        <time_frame>One year from date of transplant</time_frame>
        <population>No analysis was performed since the experimental arm was not opened</population>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant No Manipulation</title>
            <description>Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation</description>
          </group>
          <group group_id="O2">
            <title>Naive T-cell Depleted Stem Cell Transplant</title>
            <description>Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Grade II-IV Acute Graft Versus Host Disease</title>
          <population>No analysis was performed since the experimental arm was not opened</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival</title>
        <time_frame>One year</time_frame>
        <population>No analysis was performed since the experimental arm was not opened</population>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant No Manipulation</title>
            <description>Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation</description>
          </group>
          <group group_id="O2">
            <title>Naive T-cell Depleted Stem Cell Transplant</title>
            <description>Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival</title>
          <population>No analysis was performed since the experimental arm was not opened</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Immune Recovery</title>
        <description>The time to recovery of T-cell subset, B cell and NK cell recovery will be monitored along with T-Cell proliferative response to mitogens.</description>
        <time_frame>3 years</time_frame>
        <population>No analysis was performed since the experimental arm was not opened</population>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant No Manipulation</title>
            <description>Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation</description>
          </group>
          <group group_id="O2">
            <title>Naive T-cell Depleted Stem Cell Transplant</title>
            <description>Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Immune Recovery</title>
          <description>The time to recovery of T-cell subset, B cell and NK cell recovery will be monitored along with T-Cell proliferative response to mitogens.</description>
          <population>No analysis was performed since the experimental arm was not opened</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event analysis was not undertaken due to stopping the study prior to enrolling in the experimental arm.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Stem Cell Transplant No Manipulation</title>
          <description>Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation</description>
        </group>
        <group group_id="E2">
          <title>Naive T-cell Depleted Stem Cell Transplant</title>
          <description>Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mitchell Horwitz, MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-668-1045</phone>
      <email>Mitchell.Horwitz@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

